Table 1. Characteristics of studies exploring the relationship between CD147/EMMPRIN expression and tumor prognosis (Multivariate model).
| Author | Year | Country | Cancer type | Stage/grade | Number Median (range) | Age | Follow-up time Median (range) | Detection method | Cut-off | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| Natalie Reimers-10 | 2004 | Germany | Breast carcinoma | pT1-pT4 | 600 | >50y | 63m (1–176m) | TMA/IHC | score ≥ 1 | DSS |
| HC Zheng-19 | 2006 | Japan | Gastric carcinoma | 0–IV | 219 | 66.8y (38–88y) | 40.4m (0.2m–12.2y) | TMA/IHC | ≥5% | OS |
| Kazu Ueda-20 | 2006 | Japan | Endometrial carcinoma | I–IV | 112 | 55.3 ± 11.7 | NA | IHC | score > 2 | RFS |
| Qing Zhang-21 | 2007 | China | Hepatocellular carcinoma | I–IV | 111 | 47.47 ± 9.55 (24–66y) | 26m (30–1880d) | IHC | ≥1% | RFS |
| Anne B. Als-5 | 2007 | Denmark | Bladder Cancer | T4b, N2–3, M1 | 124 | 62.6y (31–78y) | 56.5 (19.5–129.8) m | IHC | κ values of 0.83 | OS |
| Wulf Sienel-22 | 2008 | Germany | Non-small-cell lung cancer | T1–T4 | 57 | 60y (37–80y) | 36 m (4–156) | IHC | score > 200 | OS |
| Xingzhu Ju-23 | 2008 | China | Cervical Cancer | Ib2–IIb | 75 | 49.7y (21–72y) | 52m (3–168m) | IHC | ≥1% | DSS |
| Yu Li-11 | 2009 | China | Breast carcinoma | infiltrating | 106 | NA | 63.5m (7–170) | TMA/IHC | ≥30% | RFS |
| Fangfang Liu-12 | 2010 | China | Breast carcinoma | Invasive | 186 | 52.5y (23–85y) | 64.8m (7–170m) | IHC | ≥1% | OS, PFS |
| Xinjie Yang-24 | 2010 | China | Adenoid cystic carcinoma of salivary glands | I–IV | 72 | NA | 76.76 ± 37.47 m; (9–178 m) | IHC | ≥5% | OS |
| Wei-De Zhong-25 | 2010 | China | Bladder cancer | T1–T4 | 101 | 68.1y (46–82y) | 36m | IHC | ≥5% | OS, PFS |
| Tongwei Chu-26 | 2011 | China | Pediatric Medulloblastoma | M0–M4 (Metastatic stage) | 56 | Paediatric patients | 5–y | IHC | ≥5% | OS |
| Yijun Xue-27 | 2011 | China | Bladder cancer | pT1–pT4 | 108 | 58.3y (31–82y) | 35.5 m (3–86m) | TMA/IHC | ≥1% | OS |
| Shaojun Zhu-28 | 2011 | China | Esophageal Squamous Cell Carcinoma | NA | 86 | 40–78y | 4–6 y | IHC | ≥5% | OS |
| Weide Zhong-29 | 2011 | China | Prostate cancer | pT2–pT3 | 240 | 61.81 ± 6.54y/61.94 ± 5.83y | NA | TMA/IHC | ≥5% | MFS, OS |
| Xuecheng Bi-30 | 2012 | China | Human seminomas | pT1–pT4 | 65 | 21.66 ± 10.18y | 5 y | IHC | ≥5% | OS |
| K Boye-31 | 2012 | Norway | Colorectal cancer | I–III | 242 | 70y (21–98 y) | 9.1y (8.2–10.0y) | IHC | ≥5% | MFS, DSS, OS |
| Zhangxuan Shou-32 | 2012 | China | Gastric Cancer | I–IV | 436 | 64y (30–91y) | >5y | TMA/IHC | ≥5% | OS |
| Albrecht Stenzinger -33 | 2012 | Germany | Colorectal cancer | I–IV | 285 | 66.6y | NA | TMA/IHC | score > 6 | OS |
| Shuhua Zhao-13 | 2013 | China | Ovarian cancer | I–IV | 146 | 52.8y (26–79y) | 36m (7–82m) | IHC | score ≥ 4 | OS, PFS |
| Ying Liu-34 | 2013 | China | Breast cancer | I–III | 189 | NA | NA | IHC | ≥10% | OS |
| Anja Rabien-35 | 2013 | Germany | Renal cell carcinoma | pN0/M0 | 181 | 60y (21–86y) | 112m (0–194m) | TMA/IHC | score ≥ 1 | OS |
| Xiaoyan Xu-36 | 2013 | China | Non-small lung cancer | I–IV | 136 | 60y (35–82y) | 28m (1–87m) | IHC | ≥1% | OS |
| Min Yang-37 | 2013 | China | Glioblastoma | NA | 206 | 53.6y (14–78y) | 12.3 m (1–60 m) | IHC | score ≥ 1 | OS |
| Yang Zhao-14 | 2013 | China | Ovarian carcinomas | I–IV | 88 | 51.2y (20–81y) | 52m (1–103m) | TMA/IHC | score ≥ 1 | RFS, OS |
| Qiang Lu-17 | 2013 | China | Osteosarcoma | IIA–III | 55 | NA | 32m (8–72m) | IHC | ≥5% | OS |
| Dake Chu-38 | 2014 | China | Gastric cancer | T1–T4 | 223 | NA | 41.8m (DFS)/58.0m (OS) | IHC | ≥5% | OS, PFS |
| Qin Xu-39 | 2014 | China | Cervical carcinoma | Ia1–IIb | 110 | NA | NA | IHC | ≥10% | OS, PFS |
| Shu Zhao-40 | 2014 | China | Breast cancer | I–III | 127 | 49y (30–68y) | NA | IHC | ≥10% | OS, PFS |
| Naohisa Futamura-16 | 2014 | Japan | Osteosarcoma | IIA–IIB | 53 | 20y (4–57y) | 72m (8–200m) | IHC | score ≥ 1 | OS, DFS |
| Jian Gao-43 | 2014 | China | Ovarian cancer | I–IV | 92 | NA | NA | IHC | ≥5% | OS |
| Luís Silva Monteiro-15 | 2014 | Portugal | Oral squamous cell carcinomas | I–IV | 74 | 62.3 ± 15.3y (25–96y) | 36.45 ± 31.7m | TMA/IHC | score > 3 | CSS |
| Shaojun Zhu-41 | 2015 | China | Hepatocellular carcinoma | NA | 50 | 31–76y | 4y | IHC | ≥5% | OS |